A side-by-side comparison of two Healthcare investors: Novo Holdings (Power Score 83/100) and Vivo Capital (Power Score 83/100), both ranked among the most active firms tracked in this category.
| Novo Holdings | Vivo Capital | |
|---|---|---|
| Power Score™ | 83/100 | 83/100 |
| Assets Managed | €93B (approx.; DKK 694bn total assets under management at 31 December 2025, per the Novo Holdings Annual Report 2025, of which DKK 407bn is the holding in Novo Nordisk) | $6.1B ("Active AUM" as of Q4 2025, the label the firm uses on its own homepage; it separately stated approximately $5.3B of regulatory assets under management in its 7 May 2025 fund-close announcement) |
| Founded | 1999 | 1996 |
| Headquarters | Hellerup, Denmark | Palo Alto, CA |
| Sectors | Pharmaceuticals, Biotech, Medtech, Healthcare, Synthetic Biology, Climate, Deep Tech, Real Estate, Infrastructure | Healthcare, Biotech, Pharmaceuticals, Life Sciences, Healthtech |
Novo Holdings A/S is the holding and investment company of the Novo Nordisk Foundation, responsible for managing the Foundation's assets and wealth. Its stated purpose is to improve people's health and the sustainability of society and the planet by generating long-term returns on the Foundation's assets. Its work splits into two parts. First, it is the controlling shareholder of the Novo Group companies Novo Nordisk A/S and Novonesis A/S, holding more than 25 per cent of the ordinary share capital of each, including all the preferred A shares, and more than 70 per cent of the votes; the firm states its strategy is to be a stable and supportive owner of the Novo Group. Second, it runs an investment portfolio in two parts: Life Science Investments, made up of the Seed, Venture, Principal Investments, Planetary Health Investments and Asia teams, and Capital Investments, which manages equities, bonds, real estate, infrastructure and private equity, builds relationships with external equity and fixed income fund managers, and makes direct public equity and bond investments. The firm says it invests in almost all life science segments including pharmaceuticals, biotechnology, medical technology, healthcare services and industrial biosolutions, across North America, Europe and Asia. It is headquartered in Hellerup, Denmark, with offices in Boston, San Francisco, London, Singapore, Shanghai and Mumbai, and states that it employs more than 200 people and has made 180-plus direct investments.
View full Novo Holdings profile →Vivo Capital describes itself as a global healthcare specialist running a multi-strategy investment platform that covers venture capital, private equity and public equity. Its investment strategy page names three distinct strategies: the Vivo Innovation Fund, which invests in venture-stage companies developing healthcare technologies or products; Vivo Capital Private Equity, which combines growth capital for companies at commercial inflection points with a buyout strategy covering leveraged buyouts, management buyouts, spin-offs and restructurings; and the Vivo Opportunity Fund, a long-only strategy investing primarily in global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies through follow-ons, PIPEs, registered directs and IPOs. The firm states it has invested in over 460 healthcare companies and operates from Palo Alto with offices in China and a presence in Singapore.
View full Vivo Capital profile →